GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » InMed Pharmaceuticals Inc (NAS:INM) » Definitions » Interest Coverage

INM (InMed Pharmaceuticals) Interest Coverage : 0 (At Loss) (As of Dec. 2024)


View and export this data going back to 2020. Start your Free Trial

What is InMed Pharmaceuticals Interest Coverage?

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income by its Interest Expense. InMed Pharmaceuticals's Operating Income for the three months ended in Dec. 2024 was $-2.21 Mil. InMed Pharmaceuticals's Interest Expense for the three months ended in Dec. 2024 was $-0.35 Mil. did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is.

The historical rank and industry rank for InMed Pharmaceuticals's Interest Coverage or its related term are showing as below:


INM's Interest Coverage is not ranked *
in the Drug Manufacturers industry.
Industry Median: 12.57
* Ranked among companies with meaningful Interest Coverage only.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.


InMed Pharmaceuticals Interest Coverage Historical Data

The historical data trend for InMed Pharmaceuticals's Interest Coverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

InMed Pharmaceuticals Interest Coverage Chart

InMed Pharmaceuticals Annual Data
Trend Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
Interest Coverage
Get a 7-Day Free Trial Premium Member Only Premium Member Only N/A - N/A N/A N/A

InMed Pharmaceuticals Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Interest Coverage Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only N/A N/A N/A N/A -

Competitive Comparison of InMed Pharmaceuticals's Interest Coverage

For the Drug Manufacturers - Specialty & Generic subindustry, InMed Pharmaceuticals's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


InMed Pharmaceuticals's Interest Coverage Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, InMed Pharmaceuticals's Interest Coverage distribution charts can be found below:

* The bar in red indicates where InMed Pharmaceuticals's Interest Coverage falls into.


;
;

InMed Pharmaceuticals Interest Coverage Calculation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

If Interest Expense is negative and Operating Income is positive, then

Interest Coverage=-1* Operating Income /Interest Expense

Else if Interest Expense is negative and Operating Income is negative, then

The company did not have earnings to cover the interest expense.

Else if Interest Expense is 0 and Long-Term Debt & Capital Lease Obligation is 0, then

The company had no debt (1).


Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

InMed Pharmaceuticals's Interest Coverage for the fiscal year that ended in Jun. 2024 is calculated as

Here, for the fiscal year that ended in Jun. 2024, InMed Pharmaceuticals's Interest Expense was $0.00 Mil. Its Operating Income was $-8.13 Mil. And its Long-Term Debt & Capital Lease Obligation was $0.65 Mil.

GuruFocus does not calculate InMed Pharmaceuticals's interest coverage with the available data.

InMed Pharmaceuticals's Interest Coverage for the quarter that ended in Dec. 2024 is calculated as

Here, for the three months ended in Dec. 2024, InMed Pharmaceuticals's Interest Expense was $-0.35 Mil. Its Operating Income was $-2.21 Mil. And its Long-Term Debt & Capital Lease Obligation was $0.53 Mil.

InMed Pharmaceuticals did not have earnings to cover the interest expense.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's Financial Strength is.


InMed Pharmaceuticals  (NAS:INM) Interest Coverage Explanation

Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.

Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .


InMed Pharmaceuticals Interest Coverage Related Terms

Thank you for viewing the detailed overview of InMed Pharmaceuticals's Interest Coverage provided by GuruFocus.com. Please click on the following links to see related term pages.


InMed Pharmaceuticals Business Description

Traded in Other Exchanges
Address
885 West Georgia Street, Suite 1445, Vancouver, BC, CAN, V6C 3E8
InMed Pharmaceuticals Inc is a Canada based clinical-stage biopharmaceutical company. The company is engaged in the research and development of novel, cannabinoid-based, and manufacturing of Pharmaceutical grade cannabinoids. Its product portfolio includes INM-755, which is used for the treatment of epidermolysis bullosa; INM-088 for the treatment of glaucoma; INM-901 for Alzheimer's disease, INM-089's pharmacological and IntegraSyn which is a manufacturing system for Pharmaceutical-Grade Cannabinoids.
Executives
Mancini Alexandra Diane Janet officer: Sr VP, Clinical Reg Affairs C/O INMED PHARMACEUTICALS INC., SUITE 310 - 815 HASTINGS STREET, VANCOUVER A1 V6C 1B4
Andrew Hull director C/O INMED PHARMACEUTICALS INC., SUITE 310 - 815 HASTINGS STREET, VANCOUVER A1 V6C 1B4
Eric A Adams director, officer: President & CEO C/O INMED PHARMACEUTICALS INC., SUITE 310 - 815 HASTINGS STREET, VANCOUVER A1 V6C 1B4
Jonathan Tegge officer: Interim CFO 217 W. MAIN STREET, SOMERVILLE NJ 08876
Sarah Li officer: VP, Accounting and Controller 310-815 WEST HASTINGS ST., VANCOUVER Z4 V6C1B4
Nicole Lemerond director 3 MURRAY HILL ROAD, SCARSDALE NY 10583
Bryan T Baldasare director 3471 RIVER HILLS DRIVE, CINCINNATI OH 45244
Brenda Edwards officer: Interim CFO 111-1232 JOHNSON ST., COQUITLAM A1 V3B 4T2
Janet P Grove director 510 WEST GEORGIA STREET, SUITE 1800, VANCOUVER A1 V5T 4T5
Bruce Colwill officer: CFO C/O INMED PHARMACEUTICALS INC., SUITE 310 - 815 HASTINGS STREET, VANCOUVER A1 V6C 1B4
Shane Aaron Johnson officer: SVP & GM of BayMedica LLC 930 TAHOE BLVD., SUITE 802-433, INCLINE VILLAGE NV 89451
Adam D. Cutler director 9301 AMBERGLEN BOULEVARD, SUITE 100, C/O MOLECULAR TEMPLATES, INC., AUSTIN TX 78729
William J Garner director 875 MAHLER ROAD, SUITE 235, BURLINGAME CA 94010
Catherine Sazdanoff director 3471 RIVER HILLS DRIVE, CINCINNATI OH 45244
Eric C Hsu officer: Sr. VP, Pre-Clinical Res/Dev C/O INMED PHARMACEUTICALS INC., SUITE 310 - 815 HASTINGS STREET, VANCOUVER A1 V6C 1B4

InMed Pharmaceuticals Headlines

From GuruFocus

Q2 2020 InMed Pharmaceuticals Inc Earnings Call Transcript

By GuruFocus Research 03-06-2024

Q3 2020 InMed Pharmaceuticals Inc Earnings Call Transcript

By GuruFocus Research 03-06-2024

Q2 2021 InMed Pharmaceuticals Inc Earnings Call Transcript

By GuruFocus Research 03-06-2024

InMed Provides Business Update and Milestones for 2023

By Stock market mentor Stock market mentor 01-10-2023

InMed Provides Update on Management Changes

By Value_Insider Value_Insider 11-17-2022

InMed Pharmaceuticals Supports Epidermolysis Bullosa Awareness Week

By Value_Insider Value_Insider 10-26-2022

InMed Announces Changes to its Board of Directors

By PurpleRose PurpleRose 08-09-2022

Q3 2021 InMed Pharmaceuticals Inc Earnings Call Transcript

By GuruFocus Research 03-06-2024